Displaying 461 - 480 of 1510
Price Effects of a Merger: Evidence from a Physicians’ Market
FTC to Join CDC Twitter Chat on Healthy Contact Lens Wear and Care
Aqua Health Labs, Inc. (PhytOriginal dietary supplements)
Doctors Hospital at Renaissance/Mission Regional Medical Center
FTC Staff Provides Additional Comment and Testimony in Tennessee Opposing Mountain States’ and Wellmont’s Certificate of Public Advantage Application
Tennessee Department of Health, Certificate of Public Advantage Hearing Testimony
Wellmont Health System/Mountain States Health Alliance
FTC Approves Sublicense for Synacthen Depot Submitted by Mallinckrodt ARD Inc.
Mallinckrodt Ard Inc. (Questcor Pharmaceuticals)
Mallinckrodt ARD Inc., formerly known as Questcor Pharmaceuticals, Inc., and its parent company, Mallinckrodt plc, agreed to pay $100 million to settle charges that they violated the antitrust laws when Questcor acquired the rights to a drug that threatened its monopoly in the U.S. market for adrenocorticotropic hormone (ACTH) drugs. Acthar is a specialty drug used as a treatment for infantile spasms, a rare seizure disorder afflicting infants, as well a drug of last resort used to treat other serious medical conditions. The complaint alleges that, while benefitting from an existing monopoly over the only U.S. ACTH drug, Acthar, Questcor illegally acquired the U.S. rights to develop a competing drug, Synacthen Depot. The acquisition stifled competition by preventing any other company from using the Synacthen assets to develop a synthetic ACTH drug, preserving Questcor’s monopoly and allowing it to maintain extremely high prices for Acthar. In addition to the $100 million monetary payment, the proposed stipulated court order, which must be approved by the federal court, requires that Questcor grant a license to develop Synacthen Depot to treat infantile spasms and nephrotic syndrome to a licensee approved by the Commission.
FTC and State Attorney General Challenge Physician Group Acquisition in North Dakota
CellMark Biopharma, LLC & Lexium International LLC
Federal Trade Commission Closes Investigation of Texas Medical Board After Texas Passes Law Expanding Telemedicine and Telehealth Services
FTC Obtains Court Approval of Divestiture of Saltzer Medical Group by Idaho-based St. Luke’s Health System
St. Luke's Health System, Ltd, and Saltzer Medical Group, P.A.
The FTC, together with the Idaho Attorney General, filed a complaint in federal district court seeking to block St. Luke’s Health System, Ltd.’s acquisition of Idaho's largest independent, multi-specialty physician practice group, Saltzer Medical Group P.A. According to the joint complaint, the combination of St. Luke’s and Saltzer would give it the market power to demand higher rates for health care services provided by primary care physicians (PCPs) in Nampa, Idaho and surrounding areas, ultimately leading to higher costs for health care consumers. The federal district court held that the acquisition violated Section 7 of the Clayton Act and the Idaho Competition Act, and ordered St. Luke’s to fully divest itself of Saltzer’s physicians and assets. The Ninth Circuit affirmed the district court ruling.
Now Hear This: Competition, Innovation, and Consumer Protection Issues in Hearing Health Care
Displaying 461 - 480 of 1510